|
|
|
|
Delaware
|
|
001-36570
|
|
45-4488360
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
[ ]
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.0001 par value
|
ZSAN
|
The Nasdaq Stock Market
|
Nominee
|
|
For
|
|
Withheld
|
|
Broker Non-Votes
|
Joseph “Jay” P. Hagan
|
|
10,615,482
|
|
2,100,105
|
|
25,091,892
|
Steven Lo
|
|
9,356,498
|
|
3,359,089
|
|
25,091,892
|
Kleanthis G. Xanthopoulos, Ph.D.
|
|
11,901,181
|
|
814,406
|
|
25,091,892
|
For
|
|
Against
|
|
Abstain
|
36,388,539
|
|
842,949
|
|
575,991
|
|
|
|
|
|
|
|
|
|
ZOSANO PHARMA CORPORATION
|
||
|
|
|
|
||
Date: June 29, 2020
|
|
|
By:
|
|
/s/ Christine Matthews
|
|
|
|
|
|
Name: Christine Matthews
|
|
|
|
|
|
Title: Chief Financial Officer
|